Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade

Weilei Hu, Guosheng Wang, Yian Wang, Matthew J. Riese, Ming You

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Abstract

Immunotherapy with monoclonal antibodies targeting immune checkpoint molecules, including programmed death-1 (PD-1), PD ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen (CTLA)-4, has become prominent in the treatment of many types of cancer. However, a significant number of patients treated with immune checkpoint inhibitors (ICIs) develop immune-related adverse events (irAEs). irAEs can affect any organ system, and although most are clinically manageable, irAEs can result in mortality or long-term morbidity. Factors that can predict irAEs remain elusive. Understanding the etiology of ICI-induced irAEs and ways to limit these adverse events are needed. In this review, we provide basic science and clinical insights on the mechanisms responsible for ICI efficacy and ICI-induced irAEs. We further provide insights into approaches that may uncouple irAEs from the ability of ICIs to kill tumor cells.

Original languageEnglish (US)
Article number101580
JournaliScience
Volume23
Issue number10
DOIs
StatePublished - Oct 23 2020

Keywords

  • Cancer
  • Clinical Medicine
  • Immunology

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade'. Together they form a unique fingerprint.

Cite this